Preferred Label : promethazine;
MeSH definition : A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative
properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation,
and also in animals.;
MeSH synonym : proazamine; prometazin;
MeSH hyponym : phensedyl; pyrethia; atosil; phenergan; pipolfen; remsed; diprazin; promet; pipolphen; prothazin; diphergan; Phenargan;
Related MeSH term : isopromethazine; rumergan; promethazine hydrochloride; Hydrochloride, Promethazine;
MeSH CAS label : 10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl-;
MeSH Related Number : 60-87-7 (Promethazine); isopromethazine; promethazine hydrochloride; 044033O3TY; R61ZEH7I1I;
Registry Number MeSH : 60-87-7;
Related CAS MeSH : 044033O3TY (Isopromethazine); R61ZEH7I1I (Promethazine hydrochloride);
Wikipedia link : https://en.wikipedia.org/wiki/Promethazine;
Codes EINECS : 200-489-2;
Is substance : O;
UNII : FF28EJQ494;
InChIKey : PWWVAXIEGOYWEE-UHFFFAOYSA-N;
Origin ID : D011398;
UMLS CUI : C0033405;
ATC code(s)
ATC code(s)
Allowable qualifiers
CISMeF manual mappings
Currated CISMeF NLP mapping
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative
properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation,
and also in animals.
https://www.has-sante.fr/jcms/p_3219452/fr/phenergan
2020
false
false
false
France
administration, oral
insurance, health, reimbursement
treatment outcome
rhinitis, allergic, seasonal
rhinitis, allergic, perennial
histamine h1 antagonists
anti-allergic agents
antipruritics
conjunctivitis, allergic
urticaria
transient insomnia
promethazine
evaluation of the transparency committee
promethazine
sleep initiation and maintenance disorders
---
https://www.legifrance.gouv.fr/jo_pdf.do?id=JORFTEXT000041450926
2020
false
false
false
France
French
legislation, pharmacy
legislation, drug
administration, oral
legislation
promethazine
---
https://www.ansm.sante.fr/actualites/conduite-a-tenir-en-cas-de-rupture-dapprovisionnement-de-polaramine-injectable
2018
false
false
false
false
France
French
pharmacovigilance note
injections
dexchlorpheniramine maleate
dexchlorpheniramine
histamine h1 antagonists
urticaria
adult
acute disease
Acute urticaria (disorder)
promethazine
promethazine
anti-allergic agents
histamine h1 antagonists
premedication
dexchlorpheniramine
chlorpheniramine
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69317889
2012
France
summary of product characteristics
package leaflet
pharmaceutical solutions
promethazine
---
http://www.has-sante.fr/jcms/c_1188940/phenergan
http://www.has-sante.fr/upload/docs/application/pdf/2012-01/phenergan_14_12_2011_avis_ct11603_11240.pdf
http://www.has-sante.fr/jcms/c_456491/phenergan
2011
France
French
promethazine
administration, oral
insurance, health, reimbursement
tablets
promethazine
rhinitis, allergic, seasonal
rhinitis, allergic, perennial
conjunctivitis
urticaria
sleep initiation and maintenance disorders
treatment outcome
anti-allergic agents
histamine h1 antagonists
antipruritics
evaluation of the transparency committee
---
http://www.cochrane.org/fr/CD005146
2011
false
true
false
France
United Kingdom
treatment outcome
review of literature
french abstract
promethazine
aggression
haloperidol
psychotic disorders
---
https://www.lecrat.fr/?s=Prom%C3%A9thazine
2009
France
French
pregnancy
promethazine
infant, newborn
anti-allergic agents
promethazine
drug information
---
https://www.has-sante.fr/jcms/c_400478
2005
France
evaluation of the transparency committee
promethazine
---
http://www.has-sante.fr/upload/docs/application/pdf/ct031940.pdf
https://www.has-sante.fr/jcms/c_400363
2004
France
French
acetaminophen
drug combinations
promethazine
histamine h1 antagonists
analgesics, non-narcotic
suppositories
administration, rectal
paracetamol, combinations excl. psycholeptics
nasopharyngitis
headache
fever
treatment outcome
antipyretics
evaluation of the transparency committee
---